Why do we focus on research? Because the link between research spending and improved survival is clear. Survival rates have dramatically improved for colorectal, breast, and prostate cancers over the last several decades along with the exponential growth in their research spending. We want to do the same for lung cancer, whose five-year survival rate is only 16%. To date, LUNGevity-funded projects represent almost $16 million spent on 100 research projects at 56 institutions in 23 states. LUNGevity research investments focus on early detection, because the survival rate jumps when lung cancer is detected while still localized. We also focus on personalizing treatment approaches through biomarkers—getting the right treatment to the right patient at the right time.
Our projects are translational, meaning that they move basic research toward clinical practice. The goal of the LUNGevity research program is to fund the research that is most likely to result in patient benefit in the foreseeable future. Thanks to our Scientific Advisory Board—a group that includes leaders in epidemiology, biostatistics, proteomics, immunotherapy, thoracic surgery, and other areas relevant to the research we support—research project applications are rigorously reviewed in a multi-step process. So we know that the strongest projects—those most likely to have the most impact in the near-term—are the ones we fund.
LUNGevity also provides a community of support and hope for everyone affected by lung cancer—through its more than 80 grassroots awareness and fundraising events held from coast to coast each year and its extensive online support and educational resources.
Our research, our events, and all of these free support resources and ways to access them are described in more detail throughout this website.